Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death‐1 checkpoint inhibitor therapy
| Autor: | Chrysalyne D. Schmults, K A O'Connell |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Cutaneous squamous cell carcinoma business.industry medicine.medical_treatment Immune checkpoint inhibitors Immunosuppression Dermatology Disease Pembrolizumab Discontinuation Infectious Diseases Internal medicine medicine Programmed death 1 Solid organ transplantation business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology. 36:45-48 |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.17407 |
| Popis: | Limited data exist on the use of immune checkpoint inhibitors (ICI) for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTR). We report a case of a SOTR who developed metastatic disease following multiple surgeries, three cycles of adjuvant radiotherapy, and minimization of immunosuppression. He was subsequently treated with pembrolizumab and achieved a complete response. However, the patient developed ICI-induced allograft rejection requiring therapy discontinuation. The allograft was salvaged following IVIg and steroids. The patient developed recurrent disease which failed rechallenge with pembrolizumab but achieved a partial response following cemiplimab administration. This case illustrates the potential to treat metastatic CSCC in a SOTR with anti-programmed death-1 therapy and preserve graft function despite allograft rejection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text